X

Trial Profile

Open Label Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Ciprofloxacin/Celecoxib Combination in Patients With ALS

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Celecoxib/ciprofloxacin (Primary)
Indications Amyotrophic lateral sclerosis
Focus Adverse reactions
Sponsors NeuroSense Therapeutics

Most Recent Events

19 Sep 2022 According to a NeuroSense Therapeutics media release, results from this trial were published in the peer-reviewed publication in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration.
19 Sep 2022 Results published in the NeuroSense Therapeutics Media Release.
23 May 2022 According to a NeuroSense Therapeutics media release, results from this study are expected Q2 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com